Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling

Molecular Cancer Therapeutics
Sarah K Nelson-TaylorRobert C Doebele

Abstract

Oncogenic rearrangements in RET are present in 1%-2% of lung adenocarcinoma patients. Ponatinib is a multi-kinase inhibitor with low-nanomolar potency against the RET kinase domain. Here, we demonstrate that ponatinib exhibits potent antiproliferative activity in RET fusion-positive LC-2/ad lung adenocarcinoma cells and inhibits phosphorylation of the RET fusion protein and signaling through ERK1/2 and AKT. Using distinct dose escalation strategies, two ponatinib-resistant LC-2/ad cell lines, PR1 and PR2, were derived. PR1 and PR2 cell lines retained expression, but not phosphorylation of the RET fusion and lacked evidence of a resistance mutation in the RET kinase domain. Both resistant lines retained activation of the MAPK pathway. Next-generation RNA sequencing revealed an oncogenic NRAS p.Q61K mutation in the PR1 cell. PR1 cell proliferation was preferentially sensitive to siRNA knockdown of NRAS compared with knockdown of RET, more sensitive to MEK inhibition than the parental line, and NRAS dependence was maintained in the absence of chronic RET inhibition. Expression of NRAS p.Q61K in RET fusion expressing TPC1 cells conferred resistance to ponatinib. PR2 cells exhibited increased expression of EGFR and AXL. EGFR inhibit...Continue Reading

References

Sep 1, 1983·Cell·E TaparowskyM Wigler
Mar 12, 2003·Genes & Development·Norman J KennedyRoger J Davis
Feb 25, 2005·The New England Journal of Medicine·Susumu KobayashiBalázs Halmos
Dec 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·James BeanWilliam Pao
Mar 18, 2009·Bioinformatics·Cole TrapnellSteven L Salzberg
Jun 10, 2009·Bioinformatics·Heng LiUNKNOWN 1000 Genome Project Data Processing Subgroup
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Jan 12, 2011·Nature Biotechnology·James T RobinsonJill P Mesirov
Jan 20, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Aidan G GilmartinSylvie G Laquerre
Mar 25, 2011·Science Translational Medicine·Lecia V SequistJeffrey A Engelman
Jan 12, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert C DoebeleD Ross Camidge
Feb 14, 2012·Nature Medicine·Doron LipsonPhilip J Stephens
Feb 14, 2012·Nature Medicine·Kengo TakeuchiYuichi Ishikawa
Feb 14, 2012·Nature Medicine·Takashi KohnoTatsuhiro Shibata
May 17, 2012·Cancer Research·Ian A PriorCarla Mattos
Jul 4, 2012·Nature Genetics·Zhenfeng ZhangTrever G Bivona
Oct 24, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lauren Averett ByersJohn V Heymach
Nov 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rui WangHaiquan Chen
Nov 17, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Daisuke MatsubaraToshiro Niki
Mar 26, 2013·The Journal of Clinical Endocrinology and Metabolism·Valentina De FalcoMassimo Santoro
Mar 28, 2013·Cancer Discovery·Alexander DrilonNaiyer Rizvi
Jul 3, 2013·Molecular and Cellular Endocrinology·Luca MologniCarlo Gambacorti-Passerini
Nov 5, 2013·The New England Journal of Medicine·J E CortesUNKNOWN PACE Investigators
Jul 2, 2014·Nature Reviews. Clinical Oncology·D Ross CamidgeLecia V Sequist
Aug 20, 2014·Cancer Research·Toni M BrandDeric L Wheeler
Sep 11, 2014·Nature Communications·Nicolas StranskyChristoph Lengauer
Sep 30, 2014·The New England Journal of Medicine·Alice T ShawA John Iafrate
Oct 29, 2014·Molecular Cancer Therapeutics·Tatsushi KodamaHiroshi Sakamoto
Feb 18, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ahnah SongDae Seog Heo
Feb 19, 2015·Oncotarget·Marilisa CargneluttiSilvia Giordano

❮ Previous
Next ❯

Citations

Oct 27, 2017·Nature Reviews. Cancer·Julia Rotow, Trever G Bivona
Jan 20, 2018·Endocrine-related Cancer·Sara RedaelliLuca Mologni
Nov 15, 2017·Nature Reviews. Clinical Oncology·Alexander DrilonDaniel S W Tan
Feb 23, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vivek SubbiahFunda Meric-Bernstam
Oct 1, 2020·Targeted Oncology·Mitchell S von ItzsteinMuhammad Shaalan Beg
Nov 15, 2018·Cancers·Francesca MusumeciSilvia Schenone
Aug 13, 2020·Therapeutic Advances in Medical Oncology·Thomas E Stinchcombe
Aug 2, 2020·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Ying-Hsia ChuPeter M Sadow
Feb 26, 2020·Cancer Discovery·Vivek Subbiah, Gilbert J Cote
Nov 9, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V SubbiahJ Wu
Nov 13, 2019·Cancer Treatment Reviews·Andrew Y LiChristian Rolfo
Feb 2, 2020·Surgical Pathology Clinics·Roberto Ruiz-Cordero, Walter Patrick Devine
Apr 4, 2021·Cancer Discovery·Mihaela AldeaJean-Charles Soria
Dec 15, 2020·Trends in Cancer·Marie-Julie NokinDavid Santamaria
Jun 3, 2021·Biomedicines·Tarek TahaAbed Agbarya
Aug 16, 2021·Trends in Cancer·Kyaw Z TheinVivek Subbiah
Oct 13, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L Tan, B J Solomon

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.